Denise Morrison said Trump's comments on Tuesday blaming "many sides" for the deadly Charlottesville, Virginia, demonstrations made her reconsider her commitment to the initiative. Johnson & Johnson's CEO Ron Gorsky was also going to leave the panel.
A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid.
Johnson & Johnson posted a 28 percent jump in fourth-quarter profit, beating Wall Street expectations, as the sale of part of its now-restructuring medical devices business offset the strong dollar and multiple charges. The results pushed up shares of the Dow component more than 3 percent.